Variability of Oxaliplatin-Induced Neuropathic Pain Symptoms in Each Cycle and Its Implications on the Management of Colorectal Cancer Patients: A Retrospective Study in South Western Sydney Local Health District Hospitals, Sydney, Australia

<div>The number (left panels, <i>N</i>) and incidence (right panels, %) of patients who developed adverse events leading to a change in treatment including peripheral neuropathy (top row, <i>N</i> = 250), haematological toxicity (middle row, <i>N</i> = 267), and gastrointestinal toxicity (bottom row, <i>N</i> = 229).</div>

Journal of Oncology

fig1

Figure 1

Figure 1: Variability of Oxaliplatin-Induced Neuropathic Pain Symptoms in Each Cycle and Its Implications on the Management of Colorectal Cancer Patients: A Retrospective Study in South Western Sydney Local Health District Hospitals, Sydney, Australia 

Figure 1 | Variability of Oxaliplatin-Induced Neuropathic Pain Symptoms in Each Cycle and Its Implications on the Management of Colorectal Cancer Patients: A Retrospective Study in South Western Sydney Local Health District Hospitals, Sydney, Australia 